Research programme: prodrug based therapeutics - Zevra Therapeutics/Novoxar
Latest Information Update: 26 Feb 2023
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 28 Nov 2022 No recent reports of development identified for research development in Unspecified in USA
- 04 May 2021 twoXAR Pharmaceuticals is now called Aria Pharmaceuticals